Austco Healthcare Ltd (AHC) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Austco Healthcare Ltd A$0.30, price A$0.26, upside +16.7%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Austco Healthcare Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range A$0.0865 – A$0.4450 · fair‑value band A$0.2210 – A$0.3740 · the A$0.2550 price screens below the A$0.2975 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Austco Healthcare in your weekly email
Every Wednesday you see whether Austco Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Austco Healthcare Limited, together with its subsidiaries, engages in the business of development, manufacture, service, supply, and distribution of healthcare communications equipment and software in Australia, New Zealand, Asia, Europe, and North America.
Show more
Austco Healthcare Limited, together with its subsidiaries, engages in the business of development, manufacture, service, supply, and distribution of healthcare communications equipment and software in Australia, New Zealand, Asia, Europe, and North America. The company offers Tacera, an IP nurse call system; Medicom, a solution for nurse call system; Pulse Mobile which allows staff to manage nurse call functions on the go and trigger workflows remotely; clinical workflow that allows healthcare staff to communicate with ancillary departments, measure adherence to protocol, and control other systems; Built-in RTLS, a nurse call platform; enterprise reporting; and integration services. It is also involved in the marketing, sales, and installation of electronic healthcare communication systems. The company was formerly known as Azure Healthcare Limited and changed its name to Austco Healthcare Limited in November 2020. Austco Healthcare Limited was founded in 1986 and is headquartered in Port Melbourne, Australia.
Stock analysis
Austco Healthcare Ltd (AHC) currently trades at A$0.2550, while our model-based Fair Value estimate is A$0.2975, implying the stock looks roughly 14.3% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of A$0.4400 per share, and 18 of the 24 models we run sit above the A$0.2550 price.
Bear case: the Asset-Based group reads lowest at A$0.0900, and 6 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: A$0.2210 (bear) to A$0.3740 (bull), the price of A$0.2550 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Austco Healthcare Ltd reported revenue of A$81.4M in FY2025 versus A$31.3M in FY2021, a compound +27.0%/yr. Reported net income was A$5.9M in FY2025, compounding +14.7%/yr from FY2021.
Key figures
Market cap A$94.5M (≈ $66.5M) · P/E ratio 12.8 · P/S ratio 0.93 · EPS (TTM) A$0.0200 · Net margin 7.3% · Return on equity 14.4% · Return on assets (EBIT) 7.6% · Operating margin 14.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 17%, AHC screens cheaper than that median.
Fair Value models
Bear A$0.2210Fair Value A$0.2975Bull A$0.3740
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (A$0.0200 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+40.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
Start year 2020 (pandemic). Over 10 years: +8.8% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+10.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11% vs 2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 13%
2025 sits 96% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about −7.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 13/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside+17% · Above median
Profitability
Return on equity (TTM)14% · Top 25%
Return on assets10% · Top 25%
Net margin (TTM)8% · Above median
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth31% · Top 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Austco Healthcare Ltd (AHC) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of A$0.2975 versus a price of A$0.2550, about +17% upside (undervalued).
What is the fair value of AHC?
Our model-based fair value for Austco Healthcare Ltd is A$0.2975 (as of Sep 23, 2026), built from audited fundamentals. The current price: A$0.2550.
What is the quality score of AHC?
Austco Healthcare Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Austco Healthcare Ltd (AHC)?
Our model-based price target is the fair value of A$0.2975 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario A$0.2210, optimistic scenario A$0.3740. It is a calculation from audited fundamentals, not an analyst target.
What is the Austco Healthcare Ltd stock forecast for 2026?
Our models put fair value at A$0.2975, about +17% upside versus a price of A$0.2550 (undervalued). Cautious scenario A$0.2210, optimistic scenario A$0.3740. The calculation is refreshed regularly with new filings.
What is the revenue of Austco Healthcare Ltd (AHC)?
Austco Healthcare Ltd reported trailing-twelve-month revenue of about A$92.7M (latest available figure, as of Sep 23, 2026).
What growth is priced into Austco Healthcare Ltd (AHC)?
For today's price to be fair in a discounted-cash-flow model, Austco Healthcare Ltd would have to grow free cash flow by -4.9 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +20.8 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of AHC use?
Our models discount Austco Healthcare Ltd at 11.0 %: a base by market capitalisation (micro), damped by beta 0.32, country premium for Australia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Austco Healthcare Ltd that is -4.9 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Austco Healthcare Ltd (AHC) delivered so far?
Over the past 5 years revenue at Austco Healthcare Ltd grew +20.8 % a year. The price currently implies -4.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Austco Healthcare Ltd (AHC) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Austco Healthcare Ltd (-4.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Austco Healthcare Ltd (AHC)?
The free-cash-flow yield on the price is 11.28 %: that much free cash flow Austco Healthcare Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Austco Healthcare Ltd (AHC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Austco Healthcare Ltd it is A$0.2975 per share (as of Sep 23, 2026), against a price of A$0.2550. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Austco Healthcare Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, AHC trades below its calculated fair value: price A$0.2550, fair value A$0.2975, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AHC?
No. The price is what the market pays today (A$0.2550); the fair value is what the company's own numbers justify (A$0.2975). For Austco Healthcare Ltd the two are A$0.0425 per share apart. That gap is exactly why we show both numbers side by side.
How much is Austco Healthcare Ltd worth?
The market values Austco Healthcare Ltd at about A$94.5M (market capitalisation, as of Sep 23, 2026). Per share that is A$0.2550; our models calculate a fair value of A$0.2975 per share.
What do the bullish and bearish scenarios say about AHC?
Our models span a range for Austco Healthcare Ltd: cautious scenario A$0.2210, base A$0.2975, optimistic A$0.3740 per share (as of Sep 23, 2026, price A$0.2550). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AHC?
Austco Healthcare Ltd trades at a price-to-earnings ratio of 12.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of A$0.2975 is built from several models across several years. Other multiples: PEG 1.2, P/B 1.3, P/S 0.7, EV/EBITDA 3.9.
What is the PEG ratio of AHC?
The PEG ratio of Austco Healthcare Ltd is 1.17 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Austco Healthcare Ltd (AHC)?
Balance-sheet figures for Austco Healthcare Ltd (as of Sep 23, 2026): return on equity 14.4%, debt of 0.07 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is AHC from its 52-week high?
Austco Healthcare Ltd trades at A$0.2550, about 43% below its 52-week high of A$0.4450 and 28% above the low of A$0.2000 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.2975 is for.
Which stocks are comparable to Austco Healthcare Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Austco Healthcare Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price A$0.2550, calculated fair value A$0.2975 (+17%), Quality Score 51/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AHC calculated?
We run Austco Healthcare Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.2975, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Austco Healthcare Ltd currently trades 17 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Austco Healthcare Ltd (AHC)?
The closing price on Sep 23, 2026 was A$0.2550. Our model-based fair value is A$0.2975, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Austco Healthcare Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Austco Healthcare Ltd
How large is the market capitalisation of Austco Healthcare Ltd (AHC)?
The market capitalisation of Austco Healthcare Ltd is A$94.5M (≈ $66.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Austco Healthcare Ltd (AHC)?
The price-to-sales ratio of Austco Healthcare Ltd is 0.93 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Austco Healthcare Ltd (AHC)?
Earnings per share at Austco Healthcare Ltd are A$0.0200 (price ÷ EPS = P/E 12.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Austco Healthcare Ltd (AHC)?
The net margin of Austco Healthcare Ltd is 7.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Austco Healthcare Ltd (AHC)?
The return on equity (ROE) of Austco Healthcare Ltd is 14.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Austco Healthcare Ltd (AHC)?
On an EBIT basis the return on assets of Austco Healthcare Ltd is 7.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Austco Healthcare Ltd (AHC)?
The operating margin of Austco Healthcare Ltd is 14.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Austco Healthcare Ltd (AHC)?
Revenue at Austco Healthcare Ltd is growing +30.7% versus a year earlier (3y avg +31.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Austco Healthcare Ltd (AHC)?
Earnings per share at Austco Healthcare Ltd are growing +59.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Austco Healthcare Ltd (AHC) hold?
Austco Healthcare Ltd holds more cash than debt, A$10.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Austco Healthcare Ltd in the live analysis
One click puts Austco Healthcare Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
